30 Participants Needed

Biospecimen Collection for Small Cell Lung Cancer

Recruiting at 2 trial locations
AK
SI
TH
DR
GK
Overseen ByGabby Kline, BA
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Indiana University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on developing a rapid autopsy program for individuals with Small Cell Lung Cancer (SCLC). The goal is to improve the process of quickly collecting tumor tissue after a patient passes away, aiding researchers in studying this aggressive cancer more effectively. As a pilot study, it tests new methods to determine their feasibility and usefulness. Individuals with an active SCLC diagnosis might find this trial suitable. As an unphased study, it offers a unique opportunity to contribute to groundbreaking research that could enhance future cancer treatments.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

Why are researchers excited about this trial?

Researchers are excited about the rapid autopsy protocol for small cell lung cancer (SCLC) because it offers new insights into the biology of this aggressive cancer. Unlike traditional treatments, which primarily focus on managing symptoms or slowing progression, this protocol aims to gather critical data from patients much faster after passing, potentially revealing how the cancer evolves and responds to treatments. This unique approach could lead to more targeted therapies and improve our understanding of why certain treatments work for some patients but not others. By examining cancer cells at various stages, researchers hope to uncover new therapeutic targets and advance the development of more effective treatments for SCLC.

Who Is on the Research Team?

SI

Shadia I. Jalal, MD

Principal Investigator

Indiana University

Are You a Good Fit for This Trial?

Inclusion Criteria

Written informed consent and HIPAA authorization for release of personal health information.
Active SCLC diagnosis

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Tissue Collection

Tumor tissue is collected post-mortem for protein and gene analysis, RNA, whole exome sequencing, and establishment of SCLC models

Immediate post-mortem

Analysis

Collected tissue is used for RNA, whole exome and whole genome sequencing, protein extraction, and development of patient-derived xenograft models

5 years

Follow-up

Participants' data is monitored for research outcomes and further analysis

5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Biospecimen Collection

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Active SCLC DiagnosisExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Indiana University

Lead Sponsor

Trials
1,063
Recruited
1,182,000+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security